**TTD: Board Resolution No.VII.03**

On July 17, 2024, Tam Duc Cardiology Hospital Joint Stock Company announced Resolution No.VII.03/NQ-HDQT as follows:

‎‎Article 1. Approve on results of specialized activities in the first 6 months of 2024:

In the first 6 months of 2024, medical examination activities have increased slightly by 1.2% compared with the same period in 2023 (39,137/38,683). Medical examination activities in the Specialized Treatment Area: In the first 6 months of 2024, outpatients in the Specialized Medical Examination Area are 10,400 cases. Inpatient treatment has decreased by 9.2% compared with the first 6 months in 2023 (2,037/2,242). Surgical operations in the first 6 months of 2024 have carried out 154 cases, decreasing 23.7% compared with the same period in 2023 (154/202). Coronary interventions have decreased by less than 9.6% compared to the first 6 months in 2023 (755/835). Cardiac electrophysiology procedures have remained equivalent to the same period in 2023 (209/210). Clinical activities in the first 6 months of 2024 have been equivalent to the same period in 2023 (477,619/477,539).

The Board of Directors of VII. 02 Approves on results of specialized activities in the first 6 months of 2024.

‎‎Article 2. Approve on the financial results in the first 6 months of 2024:

1 The financial results in the first 6 months in 2024:

|  |  |  |
| --- | --- | --- |
|  | Plan 2024 | Results 06.2024 |
| Revenue: | VND700 billion | VND370.22 billion |
| Profit before tax: | VND90 billion | VND38.14 billion |
| Profit after tax: | VND82 billion | VND33.86 billion |

Compared with the same period in 2023, revenue has increased by 1.9%, profit before tax has decreased 21.3%, and profit after tax decreased 21.4%.

Compared with plan 2024, revenue has reached 52.9%, profit before tax has reached 42.4%, and profit after tax has reached 41.3%.

The rate of profit before tax/Total revenue of the first 6 months in 2024 is 10.3%.

In the first 6 months of 2024, revenue has increased slightly but expenses have increased more than in the first 6 months of 2023. Expenses have increased due to some main reasons: The increase in salary costs is due to scheduled salary raises, and adjustments in income in the second half of 2023. Depreciation and amortization expenses increased as investments began allocating costs in the latter half of 2023. The higher materials-to-revenue ratio persists due to various factors. The disease structure, revenue share from drug sales, and coronary intervention and cardiac electrophysiology activities have increased. The rate of profit and inpatient revenue, coronary interventions, and cardiac electrophysiology procedures for insured patients is very low because pharmaceuticals and medical supplies are reimbursed according to healthcare insurance regulations at cost rather than at a markup. Currently, the percentage of inpatients with health insurance has significantly increased, accounting for over 80% of all inpatient admissions.

The Board of Directors of VII. 02 approves on results of the financial activities in the first 6 months of 2024.

‎‎Article 3. Dividend prepayment for Period 1 2024:

The General Meeting of Shareholders dated April 27, 2024 approved on dividend 2024 as 33%/par value. The dividend prepayment grade for period 1 in 2024 is 10%/par value implemented on August 2024.

The Board of Directors of VII. 02 Approves on a decision on dividend prepayment for period 1 2024 as 10%/par value, the record date is August 01, 2024, and the dividend prepayment date is August 16, 2024.

‎‎Article 4. Decision to proceed with the bidding process for the System for Coronary Angiography and Intervention (DSA4):

The Meeting of Shareholders on April 27, 2024, decided to procure the System for Coronary Angiography and Intervention (DSA4) priced at approximately less than 20 billion, with a configuration suitable for professional requirements and assigned the Board of Directors to implement a competitive bidding process.

The Board of Directors of VII. 02 decided to adopt a competitive bidding process to procure the System for Coronary Angiography and Intervention (DSA4) priced at approximately under 20 billion. Implement in August 2024 and sign a contract in October 2024.

‎‎Article 5. ECG stress test machine

The Board of Directors of VII. 02 Approves on policy on purchasing 1 ECG stress test machine for the medical examination department, assign the Board of Managers to research and decide to select a suitable model on technique and price.